Liver fibrosis and transient elastography (TE) correlation in hepatitis C virus (HCV)-infected patients with compensated advanced chronic liver disease (cACLD) after sustained virological response (SVR) is unknown. AimsTo evaluate TE accuracy at identifying cirrhosis 3 years after HCV-eradication. MethodsProspective, multi-centric study including HCV-cACLD patients before direct-acting antivirals (DAA). Diagnostic accuracy of TE (area under ROC,… Continue reading #Elastography is unable to exclude #cirrhosis after sustained virological response in #HCV-infected patients with advanced chronic liver disease
Category: Hepatology
#Cysteamine Decreases Low‐Density Lipoprotein Oxidation, Causes Regression of #Atherosclerosis, and Improves #Liver and Muscle Function in Low‐Density Lipoprotein Receptor–Deficient Mice
We have shown previously that low‐density lipoprotein (LDL) can be oxidized in the lysosomes of macrophages, that this oxidation can be inhibited by cysteamine, an antioxidant that accumulates in lysosomes, and that this drug decreases atherosclerosis in LDL receptor–deficient mice fed a high‐fat diet. We have now performed a regression study with cysteamine, which is… Continue reading #Cysteamine Decreases Low‐Density Lipoprotein Oxidation, Causes Regression of #Atherosclerosis, and Improves #Liver and Muscle Function in Low‐Density Lipoprotein Receptor–Deficient Mice
#Pradefovir Treatment in Patients with Chronic Hepatitis #B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial
Pradefovir is a liver-targeted prodrug of adefovir, a nucleotide analog with antiviral activity against hepatitis B virus (HBV) DNA polymerase. This phase 2 study compared the efficacy and safety of oral pradefovir (30mg, 45mg, 60mg, and 75mg) versus tenofovir disoproxil fumarate (TDF; 300mg) and aimed to identify the most appropriate dose of pradefovir for the… Continue reading #Pradefovir Treatment in Patients with Chronic Hepatitis #B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial
Plasma Levels of #Homocysteine is Associated with Liver #Fibrosis in Health Check-Up Population
Studies have shown a link between homocysteine (Hcy) and heart diseases, kidney diseases, cerebrovascular diseases, liver diseases, and other pathological conditions. However, the relationship between Hcy and liver fibrosis (LF) is unclear. Here, we studied the link between plasma Hcy concentration and LF. Methods: We determined and recorded the plasma Hcy concentration, general biochemical parameters,… Continue reading Plasma Levels of #Homocysteine is Associated with Liver #Fibrosis in Health Check-Up Population
#NONALCOHOLIC FATTY LIVER DISEASE-RELATED RISK OF #CARDIOVASCULAR DISEASE AND OTHER CARDIAC COMPLICATIONS
Nonalcoholic fatty liver disease (NAFLD) affects approximately ~25% of the global adult population. The aim of this narrative review is to describe the associations between NAFLD and cardiovascular disease (CVD), arrhythmias, cardiac conduction defects, myocardial remodelling and heart failure. We also discuss the potential mechanisms that mediate or attenuate the strength of these associations, and… Continue reading #NONALCOHOLIC FATTY LIVER DISEASE-RELATED RISK OF #CARDIOVASCULAR DISEASE AND OTHER CARDIAC COMPLICATIONS
The changing characteristics of patients infected with chronic hepatitis #C virus from 2014 to 2019: Real-world data from the German #Hepatitis C-Registry (DHC-R)
The number of patients diagnosed with hepatitis C virus (HCV) is markedly higher than the number initiating treatment indicating gaps in the care cascade, likely centered around reaching at-risk populations. Understanding changing characteristics of patients with HCV allows for targeted programs that increase linkage to care. We investigated changes in demographic and clinical characteristics of… Continue reading The changing characteristics of patients infected with chronic hepatitis #C virus from 2014 to 2019: Real-world data from the German #Hepatitis C-Registry (DHC-R)
Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced #hepatocellular carcinoma
Importance: Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. Despite the recent approval of several new agents, long-term disease control remains elusive for most patients. Administration of 27.12 MHz radiofrequency (RF) electromagnetic fields (EMF) by means of a spoon-shaped antenna (TheraBionic P1 device) placed on the anterior part of the tongue… Continue reading Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced #hepatocellular carcinoma
#EGFR activation limits the response of #liver cancer to lenvatinib
Hepatocellular carcinoma (HCC)—the most common form of liver cancer—is an aggressive malignancy with few effective treatment options1. Lenvatinib is a small-molecule inhibitor of multiple receptor tyrosine kinases that is used for the treatment of patients with advanced HCC, but this drug has only limited clinical benefit2. Here, using a kinome-centred CRISPR–Cas9 genetic screen, we show… Continue reading #EGFR activation limits the response of #liver cancer to lenvatinib
Effects of #Tamoxifen vs. Toremifene on #fatty liver development and lipid profiles in #breast Cancer
Tamoxifen (TAM) and Toremifene (TOR), two kinds of selective estrogen receptor modulators (SERMs), have equal efficacy in breast cancer patients. However, TAM has been proved to affect serum lipid profiles and cause fatty liver disease. The study aimed to compare the effects of TAM and TOR on fatty liver development and lipid profiles. MethodsThis study… Continue reading Effects of #Tamoxifen vs. Toremifene on #fatty liver development and lipid profiles in #breast Cancer
